BioZorb litigation
Lawsuits allege that the BioZorb tissue marker, implanted during breast cancer treatment and recalled in 2024, failed to absorb as promised and caused pain, migration, and additional surgery.
Accepting cases
What the lawsuits allege
The BioZorb marker was supposed to dissolve harmlessly over about a year while marking a lumpectomy site for radiation. The FDA logged hundreds of reports of the device persisting, shifting, or eroding, and a Class I recall followed. The litigation alleges women undergoing breast cancer treatment were never warned the marker might become a problem of its own.
Injuries named in the litigation
- Pain and discomfort at the implant site
- Device migration or erosion through skin
- Infection and fluid buildup
- Surgical removal
Who may qualify
If you received a BioZorb marker during breast surgery and experienced persistent pain, migration, infection, or removal surgery, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.